## Seishi Ogawa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6117789/publications.pdf

Version: 2024-02-01

460 papers 26,602 citations

9234 74 h-index 148 g-index

475 all docs

475 docs citations

475 times ranked

32011 citing authors

#	Article	IF	CITATIONS
1	Frequent pathway mutations of splicing machinery in myelodysplasia. Nature, 2011, 478, 64-69.	13.7	1,764
2	Integrated molecular analysis of clear-cell renal cell carcinoma. Nature Genetics, 2013, 45, 860-867.	9.4	955
3	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022, 140, 1200-1228.	0.6	814
4	Oncogenic mutations of ALK kinase in neuroblastoma. Nature, 2008, 455, 971-974.	13.7	795
5	Mutational landscape and clonal architecture in grade II and III gliomas. Nature Genetics, 2015, 47, 458-468.	9.4	729
6	Integrated molecular analysis of adult T cell leukemia/lymphoma. Nature Genetics, 2015, 47, 1304-1315.	9.4	659
7	A Robust Algorithm for Copy Number Detection Using High-Density Oligonucleotide Single Nucleotide Polymorphism Genotyping Arrays. Cancer Research, 2005, 65, 6071-6079.	0.4	593
8	Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nature Genetics, 2014, 46, 171-175.	9.4	542
9	AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nature Medicine, 2004, 10, 299-304.	15.2	538
10	Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature, 2016, 534, 402-406.	13.7	536
11	Genomic and molecular characterization of esophageal squamous cell carcinoma. Nature Genetics, 2014, 46, 467-473.	9.4	523
12	Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. New England Journal of Medicine, 2015, 373, 35-47.	13.9	508
13	Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature, 2019, 565, 312-317.	13.7	476
14	Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature, 2009, 460, 904-908.	13.7	380
15	Clinical significance of somatic mutation in unexplained blood cytopenia. Blood, 2017, 129, 3371-3378.	0.6	379
16	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	15.2	372
17	Dynamics of clonal evolution in myelodysplastic syndromes. Nature Genetics, 2017, 49, 204-212.	9.4	348
18	Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell, 2015, 27, 658-670.	7.7	341

#	Article	IF	CITATIONS
19	Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nature Genetics, 2013, 45, 1232-1237.	9.4	334
20	The landscape of somatic mutations in Down syndrome–related myeloid disorders. Nature Genetics, 2013, 45, 1293-1299.	9.4	324
21	The genomic landscape of nasopharyngeal carcinoma. Nature Genetics, 2014, 46, 866-871.	9.4	317
22	SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood, 2012, 120, 3080-3088.	0.6	272
23	Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood, 2017, 129, 2347-2358.	0.6	268
24	Genomic Landscape of Esophageal Squamous Cell Carcinoma inÂa Japanese Population. Gastroenterology, 2016, 150, 1171-1182.	0.6	265
25	Generation of Alveolar Epithelial Spheroids via Isolated Progenitor Cells from Human Pluripotent Stem Cells. Stem Cell Reports, 2014, 3, 394-403.	2.3	260
26	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
27	Genetics of MDS. Blood, 2019, 133, 1049-1059.	0.6	241
28	Somatic SETBP1 mutations in myeloid malignancies. Nature Genetics, 2013, 45, 942-946.	9.4	229
29	Highly Sensitive Method for Genomewide Detection of Allelic Composition in Nonpaired, Primary Tumor Specimens by Use of Affymetrix Single-Nucleotide–Polymorphism Genotyping Microarrays. American Journal of Human Genetics, 2007, 81, 114-126.	2.6	227
30	Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro-Oncology, 2018, 20, 66-77.	0.6	225
31	Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients. Cancer Discovery, 2014, 4, 1088-1101.	7.7	213
32	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia, 2019, 33, 1747-1758.	3.3	195
33	<i>SF3B1</i> -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood, 2020, 136, 157-170.	0.6	195
34	Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. Nature Communications, 2015, 6, 6042.	5.8	192
35	ACTN1 Mutations Cause Congenital Macrothrombocytopenia. American Journal of Human Genetics, 2013, 92, 431-438.	2.6	186
36	Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood, 2015, 126, 2491-2501.	0.6	180

#	Article	IF	CITATIONS
37	An empirical Bayesian framework for somatic mutation detection from cancer genome sequencing data. Nucleic Acids Research, 2013, 41, e89-e89.	6.5	177
38	Recurrent somatic mutations underlie corticotropin-independent Cushing's syndrome. Science, 2014, 344, 917-920.	6.0	177
39	Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nature Communications, 2016, 7, 10767.	5.8	177
40	Frequent mutations that converge on the NFKBIZ pathway in ulcerative colitis. Nature, 2020, 577, 260-265.	13.7	168
41	Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2019, 37, 375-385.	0.8	163
42	Clonal hematopoiesis in acquired aplastic anemia. Blood, 2016, 128, 337-347.	0.6	158
43	Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients. Blood, 2013, 122, 3206-3209.	0.6	156
44	Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood, 2011, 118, 6601-6609.	0.6	153
45	Defective Epstein–Barr virus in chronic active infection and haematological malignancy. Nature Microbiology, 2019, 4, 404-413.	5.9	152
46	Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma. Nature Communications, 2015, 6, 7557.	5.8	149
47	Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia, 2019, 33, 2867-2883.	3.3	148
48	Gainâ€ofâ€function mutations and copy number increases of Notch2 in diffuse large Bâ€cell lymphoma. Cancer Science, 2009, 100, 920-926.	1.7	144
49	Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. Nature Communications, 2018, 9, 3649.	5.8	140
50	Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia, 2018, 32, 1908-1919.	3.3	137
51	Integrated Multiregional Analysis Proposing a New Model of Colorectal Cancer Evolution. PLoS Genetics, 2016, 12, e1005778.	1.5	134
52	Clonal expansion in non-cancer tissues. Nature Reviews Cancer, 2021, 21, 239-256.	12.8	133
53	Cell Therapy Using Human Induced Pluripotent Stem Cell-Derived Renal Progenitors Ameliorates Acute Kidney Injury in Mice. Stem Cells Translational Medicine, 2015, 4, 980-992.	1.6	130
54	Splicing factor mutations and cancer. Wiley Interdisciplinary Reviews RNA, 2014, 5, 445-459.	3.2	126

#	Article	IF	Citations
55	Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood, 2018, 131, 215-225.	0.6	124
56	Clonal evolution in myelodysplastic syndromes. Nature Communications, 2017, 8, 15099.	5.8	118
57	Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome–negative myeloproliferative neoplasms. Blood, 2010, 115, 2882-2890.	0.6	116
58	Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation. Blood, 2010, 115, 3158-3161.	0.6	105
59	A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy. Cell Reports, 2017, 19, 1874-1887.	2.9	104
60	Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria. Journal of Clinical Investigation, 2014, 124, 4529-4538.	3.9	103
61	Mutations in the Gene Encoding the E2 Conjugating Enzyme UBE2T Cause Fanconi Anemia. American Journal of Human Genetics, 2015, 96, 1001-1007.	2.6	100
62	Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nature Genetics, 2017, 49, 1274-1281.	9.4	100
63	Abnormal hematopoiesis and autoimmunity in human subjects with germline IKZF1 mutations. Journal of Allergy and Clinical Immunology, 2017, 140, 223-231.	1.5	99
64	Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood, 2016, 127, 596-604.	0.6	98
65	Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia, 2019, 33, 1687-1699.	3.3	98
66	Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. Blood, 2019, 133, 1140-1151.	0.6	96
67	Genomic landscape of liposarcoma. Oncotarget, 2015, 6, 42429-42444.	0.8	94
68	Regeneration of CD8αβ T Cells from T-cell–Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity. Cancer Research, 2016, 76, 6839-6850.	0.4	93
69	Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. Cancer Cell, 2019, 36, 123-138.e10.	7.7	93
70	Two Aldehyde Clearance Systems Are Essential to Prevent Lethal Formaldehyde Accumulation in Mice and Humans. Molecular Cell, 2020, 80, 996-1012.e9.	4.5	92
71	Haploinsufficiency of TNFAIP3 (A20) by germline mutation is involved in autoimmune lymphoproliferative syndrome. Journal of Allergy and Clinical Immunology, 2017, 139, 1914-1922.	1.5	91
72	Loss of function mutations in <i>RPL27</i> and <i>RPS27</i> identified by wholeâ€exome sequencing in Diamondâ€Blackfan anaemia. British Journal of Haematology, 2015, 168, 854-864.	1.2	87

#	Article	IF	CITATIONS
73	Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase δ syndrome–like immunodeficiency. Journal of Allergy and Clinical Immunology, 2016, 138, 1672-1680.e10.	1.5	87
74	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood, 2015, 126, 907-907.	0.6	85
75	Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis. Oncogene, 2001, 20, 88-96.	2.6	83
76	Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood, 2016, 128, 2666-2670.	0.6	82
77	A temporal shift of the evolutionary principle shaping intratumor heterogeneity in colorectal cancer. Nature Communications, 2018, 9, 2884.	5.8	82
78	Highly Efficient Ex Vivo Expansion of Human Hematopoietic Stem Cells Using Delta1-Fc Chimeric Protein. Stem Cells, 2006, 24, 2456-2465.	1.4	79
79	Integrated molecular profiling of juvenile myelomonocytic leukemia. Blood, 2018, 131, 1576-1586.	0.6	78
80	Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis. Nature Medicine, 2021, 27, 1239-1249.	15.2	78
81	Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia. Cancer Research, 2017, 77, 390-400.	0.4	77
82	Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma. Cancer Immunology Research, 2016, 4, 463-471.	1.6	76
83	The E-Id Protein Axis Specifies Adaptive Lymphoid Cell Identity and Suppresses Thymic Innate Lymphoid Cell Development. Immunity, 2017, 46, 818-834.e4.	6.6	73
84	Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma. Blood Advances, 2019, 3, 588-595.	2.5	73
85	ATP11C is a major flippase in human erythrocytes and its defect causes congenital hemolytic anemia. Haematologica, 2016, 101, 559-565.	1.7	72
86	Gain-of-function <i>IKBKB</i> mutation causes human combined immune deficiency. Journal of Experimental Medicine, 2018, 215, 2715-2724.	4.2	69
87	The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes. Journal of Clinical Investigation, 2017, 127, 2206-2221.	3.9	69
88	Biallelic <i>DICER1</i> Mutations in Sporadic Pleuropulmonary Blastoma. Cancer Research, 2014, 74, 2742-2749.	0.4	67
89	KLF5 Regulates the Integrity and Oncogenicity of Intestinal Stem Cells. Cancer Research, 2014, 74, 2882-2891.	0.4	66
90	Clinical utility of next-generation sequencing for inherited bone marrow failure syndromes. Genetics in Medicine, 2017, 19, 796-802.	1.1	66

#	Article	IF	Citations
91	Early diagnosis of central nervous system aspergillosis using polymerase chain reaction, latex agglutination test, and enzyme-linked immunosorbent assay. British Journal of Haematology, 1999, 106, 536-537.	1.2	65
92	Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. Blood, 2012, 119, e96-e99.	0.6	65
93	Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell, 2021, 39, 793-809.e8.	7.7	65
94	Gene expression and risk of leukemic transformation in myelodysplasia. Blood, 2017, 130, 2642-2653.	0.6	64
95	Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice. Blood, 2018, 131, 621-635.	0.6	64
96	Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. Science Immunology, 2021, 6, eabc6424.	5.6	64
97	North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. Blood, 2018, 132, 1507-1518.	0.6	63
98	Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia. Blood, 2015, 125, 706-709.	0.6	60
99	Wholeâ€exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia. British Journal of Haematology, 2016, 175, 476-489.	1.2	60
100	Genomon ITDetector: a tool for somatic internal tandem duplication detection from cancer genome sequencing data. Bioinformatics, 2015, 31, 116-118.	1.8	58
101	A comprehensive characterization of <i>cis</i> -acting splicing-associated variants in human cancer. Genome Research, 2018, 28, 1111-1125.	2.4	56
102	Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designation. Haematologica, 2012, 97, 1845-1849.	1.7	54
103	Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer. Clinical Cancer Research, 2018, 24, 6433-6446.	3.2	54
104	Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. Nature Communications, 2019, 10, 5386.	5.8	53
105	Derivation of functional mature neutrophils from human embryonic stem cells. Blood, 2009, 113, 6584-6592.	0.6	51
106	Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia. Blood Advances, 2019, 3, 3157-3169.	2.5	51
107	Combined Cohesin–RUNX1 Deficiency Synergistically Perturbs Chromatin Looping and Causes Myelodysplastic Syndromes. Cancer Discovery, 2020, 10, 836-853.	7.7	51
108	Origins of myelodysplastic syndromes after aplastic anemia. Blood, 2017, 130, 1953-1957.	0.6	50

#	Article	IF	CITATIONS
109	Oncogenic mutations of <i>ALK</i> in neuroblastoma. Cancer Science, 2011, 102, 302-308.	1.7	49
110	Extensive gene deletions in Japanese patients with Diamond-Blackfan anemia. Blood, 2012, 119, 2376-2384.	0.6	49
111	Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase δ syndrome type 1. Journal of Allergy and Clinical Immunology, 2019, 143, 266-275.	1.5	49
112	Frequent genetic alterations in immune checkpoint–related genes in intravascular large B-cell lymphoma. Blood, 2021, 137, 1491-1502.	0.6	49
113	GATA2 and secondary mutations in familial myelodysplastic syndromes and pediatric myeloid malignancies. Haematologica, 2015, 100, e398-e401.	1.7	48
114	The BRG1/SOX9 axis is critical for acinar cell–derived pancreatic tumorigenesis. Journal of Clinical Investigation, 2018, 128, 3475-3489.	3.9	48
115	Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome. Nature Cell Biology, 2022, 24, 299-306.	4.6	47
116	Evolutionary basis of HLA-DPB1 alleles affects acute GVHD in unrelated donor stem cell transplantation. Blood, 2018, 131, 808-817.	0.6	46
117	Single-cell analysis based dissection of clonality in myelofibrosis. Nature Communications, 2020, 11, 73.	5 <b>.</b> 8	46
118	Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. Experimental Hematology, 2008, 36, 1471-1479.	0.2	44
119	Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. Leukemia Research, 2018, 66, 20-27.	0.4	44
120	Whole-genome landscape of adult T-cell leukemia/lymphoma. Blood, 2022, 139, 967-982.	0.6	44
121	Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor. Journal of the National Cancer Institute, 2017, 109, .	3.0	43
122	Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. European Urology Focus, 2017, 3, 421-427.	1.6	43
123	Genomewide screening of DNA copy number changes in chronic myelogenous leukemia with the use of high-resolution array-based comparative genomic hybridization. Genes Chromosomes and Cancer, 2006, 45, 482-494.	1.5	41
124	The transcription factor E2A activates multiple enhancers that drive <i>Rag</i> expression in developing T and B cells. Science Immunology, 2020, 5, .	5.6	41
125	Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia. Leukemia, 2021, 35, 1365-1379.	3.3	41
126	Wholeâ€genome profiling of chromosomal aberrations in hepatoblastoma using highâ€density singleâ€nucleotide polymorphism genotyping microarrays. Cancer Science, 2008, 99, 564-570.	1.7	39

#	Article	IF	Citations
127	Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia. Nature Communications, 2021, 12, 2833.	5.8	39
128	SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood, 2010, 115, 1049-1053.	0.6	38
129	Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes. Blood, 2018, 132, 2309-2313.	0.6	38
130	Recurrent <i>RARB</i> Translocations in Acute Promyelocytic Leukemia Lacking <i>RARA</i> Translocation. Cancer Research, 2018, 78, 4452-4458.	0.4	37
131	Splicing factor mutations in myelodysplasia. International Journal of Hematology, 2012, 96, 438-442.	0.7	36
132	<i>TERT</i> promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver diseaseâ€related hepatocellular carcinoma. International Journal of Cancer, 2016, 139, 2512-2518.	2.3	36
133	Significance of perivascular tumour cells defined by CD109 expression in progression of glioma. Journal of Pathology, 2017, 243, 468-480.	2.1	36
134	Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma. Cancer Research, 2020, 80, 1875-1884.	0.4	36
135	Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT. Blood, 2018, 131, 1846-1857.	0.6	35
136	Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS). Annals of Hematology, 2013, 92, 1-9.	0.8	34
137	Recurrent genetic defects on chromosome 5q in myeloid neoplasms. Oncotarget, 2017, 8, 6483-6495.	0.8	34
138	Single-Nucleotide Polymorphism Array Karyotyping in Clinical Practice: Where, When, and How?. Seminars in Oncology, 2012, 39, 13-25.	0.8	33
139	De Novo Mutations Activating Germline TP53 in an Inherited Bone-Marrow-Failure Syndrome. American Journal of Human Genetics, 2018, 103, 440-447.	2.6	33
140	Comprehensive analysis of genetic aberrations linked to tumorigenesis in regenerative nodules of liver cirrhosis. Journal of Gastroenterology, 2019, 54, 628-640.	2.3	33
141	Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia. Blood Advances, 2020, 4, 5165-5173.	2.5	33
142	Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. New England Journal of Medicine, 2015, 373, 1673-1676.	13.9	32
143	LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells. Blood, 2020, 136, 684-697.	0.6	32
144	Deregulated Intracellular Signaling by Mutated c-CBL in Myeloid Neoplasms. Clinical Cancer Research, 2010, 16, 3825-3831.	3.2	31

#	Article	IF	CITATIONS
145	Genome-wide surveillance of mismatched alleles for graft-versus-host disease in stem cell transplantation. Blood, 2015, 126, 2752-2763.	0.6	31
146	Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy. Nature Communications, 2021, 12, 5547.	5.8	31
147	Molecular characterization of the recurrent unbalanced translocation der(1;7)(q10;p10). Blood, 2003, 102, 2597-2604.	0.6	30
148	Adult Tâ€eell leukemia cells are characterized by abnormalities of <scp><i>Helios</i></scp> expression that promote T cell growth. Cancer Science, 2013, 104, 1097-1106.	1.7	30
149	Variegated RHOA mutations in human cancers. Experimental Hematology, 2016, 44, 1123-1129.	0.2	30
150	Exome sequencing identified <i>RPS15A</i> as a novel causative gene for Diamond-Blackfan anemia. Haematologica, 2017, 102, e93-e96.	1.7	30
151	Integrated multiomics analysis of hepatoblastoma unravels its heterogeneity and provides novel druggable targets. Npj Precision Oncology, 2020, 4, 20.	2.3	30
152	Autonomous feedback loop of RUNX1-p53-CBFB in acute myeloid leukemia cells. Scientific Reports, 2017, 7, 16604.	1.6	29
153	Identification of a SRC-like tyrosine kinase gene, FRK, fused with ETV6 in a patient with acute myelogenous leukemia carrying a $t(6;12)(q21;p13)$ translocation. Genes Chromosomes and Cancer, 2005, 42, 269-279.	1.5	28
154	Genetic and transcriptional landscape of plasma cells in POEMS syndrome. Leukemia, 2019, 33, 1723-1735.	3.3	28
155	Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of $\langle i \rangle CDX2 \langle i \rangle$ and $\langle i \rangle IDH1/2 \langle i \rangle$ mutations. Blood, 2022, 139, 1850-1862.	0.6	28
156	Infection perturbs Bach2- and Bach1-dependent erythroid lineage â€~choice' to cause anemia. Nature Immunology, 2018, 19, 1059-1070.	7.0	27
157	RNA fusions involving <i>CD28</i> are rare in peripheral T-cell lymphomas and concentrate mainly in those derived from follicular helper T cells. Haematologica, 2018, 103, e360-e363.	1.7	27
158	Late-Onset Combined Immunodeficiency with a Novel IL2RG Mutation and Probable Revertant Somatic Mosaicism. Journal of Clinical Immunology, 2015, 35, 610-614.	2.0	26
159	Molecular pathogenesis of disease progression in MLL-rearranged AML. Leukemia, 2019, 33, 612-624.	3.3	26
160	Novel neuroblastoma amplified sequence (NBAS) mutations in a Japanese boy with fever-triggered recurrent acute liver failure. Human Genome Variation, 2019, 6, 2.	0.4	26
161	<scp>NOTCH /scp&gt;1 pathway activating mutations and clonal evolution in pediatric Tâ€eell acute lymphoblastic leukemia. Cancer Science, 2019, 110, 784-794.</scp>	1.7	26
162	High-risk HLA alleles for severe acute graft- <i>versus</i> -host disease and mortality in unrelated donor bone marrow transplantation. Haematologica, 2016, 101, 491-498.	1.7	25

#	Article	IF	CITATIONS
163	PIEZO1 gene mutation in a Japanese family with hereditary high phosphatidylcholine hemolytic anemia and hemochromatosis-induced diabetes mellitus. International Journal of Hematology, 2016, 104, 125-129.	0.7	25
164	Integrated Molecular Characterization of the Lethal Pediatric Cancer Pancreatoblastoma. Cancer Research, 2018, 78, 865-876.	0.4	25
165	Aberrant DNA Methylation Is Associated with a Poor Outcome in Juvenile Myelomonocytic Leukemia. PLoS ONE, 2015, 10, e0145394.	1.1	25
166	Detection of the G17V RHOA Mutation in Angioimmunoblastic T-Cell Lymphoma and Related Lymphomas Using Quantitative Allele-Specific PCR. PLoS ONE, 2014, 9, e109714.	1.1	24
167	Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL. Scientific Reports, 2019, 9, 10004.	1.6	24
168	Clinical Characteristics of Patients with Coronavirus Disease (COVID-19): Preliminary Baseline Report of Japan COVID-19 Task Force, a Nationwide Consortium to Investigate Host Genetics of COVID-19. International Journal of Infectious Diseases, 2021, 113, 74-81.	1.5	24
169	Unbiased Detection of Driver Mutations in Extramammary Paget Disease. Clinical Cancer Research, 2021, 27, 1756-1765.	3.2	24
170	Hepatoblastoma in a Patient with Sotos Syndrome. Journal of Pediatrics, 2009, 155, 937-939.	0.9	23
171	HapMuC: somatic mutation calling using heterozygous germ line variants near candidate mutations. Bioinformatics, 2014, 30, 3302-3309.	1.8	23
172	Clinical significance and origin of leukocytes that lack HLA-A allele expression in patients with acquired aplastic anemia. Experimental Hematology, 2016, 44, 931-939.e3.	0.2	23
173	Hypoxic adaptation of leukemic cells infiltrating the CNS affords a therapeutic strategy targeting VEGFA. Blood, 2017, 129, 3126-3129.	0.6	23
174	BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma. International Journal of Hematology, 2017, 105, 465-469.	0.7	23
175	Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis. Oncotarget, 2017, 8, 107513-107529.	0.8	23
176	Dysregulation of Epstein-Barr Virus Infection in Hypomorphic ZAP70 Mutation. Journal of Infectious Diseases, 2018, 218, 825-834.	1.9	22
177	Myelodysplastic Syndrome-Associated SRSF2 Mutations Cause Splicing Changes by Altering Binding Motif Sequences. Frontiers in Genetics, 2019, 10, 338.	1.1	22
178	Pathogenic mutations identified by a multimodality approach in $117$ Japanese Fanconi anemia patients. Haematologica, $2019,104,1962$ - $1973$ .	1.7	22
179	Genetic analysis of a case of Helicobacter pylori-uninfected intramucosal gastric cancer in a family with hereditary diffuse gastric cancer. Gastric Cancer, 2019, 22, 892-898.	2.7	22
180	Clinical and genetic features of dyskeratosis congenita, cryptic dyskeratosis congenita, and Hoyeraal-Hreidarsson syndrome in Japan. International Journal of Hematology, 2015, 102, 544-552.	0.7	21

#	Article	lF	Citations
181	Novel lincRNA SLINKY is a prognostic biomarker in kidney cancer. Oncotarget, 2017, 8, 18657-18669.	0.8	21
182	Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial. Blood, 2022, 139, 1593-1597.	0.6	21
183	BRCC3 mutations in myeloid neoplasms. Haematologica, 2015, 100, 1051-7.	1.7	20
184	Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance. Experimental Hematology, 2015, 43, 32-43.e35.	0.2	20
185	Sustained clonal hematopoiesis by HLA-lacking hematopoietic stem cells without driver mutations in aplastic anemia. Blood Advances, 2018, 2, 1000-1012.	2.5	20
186	Novel DDX41 variants in Thai patients with myeloid neoplasms. International Journal of Hematology, 2020, 111, 241-246.	0.7	20
187	Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants. Communications Biology, 2020, 3, 578.	2.0	20
188	Whole-Exome Sequencing-Based Approach for Germline Mutations in Patients with Inborn Errors of Immunity. Journal of Clinical Immunology, 2020, 40, 729-740.	2.0	20
189	Analysis of disease model iPSCs derived from patients with a novel Fanconi anemia–like IBMFS <i>ADH5/ALDH2</i> deficiency. Blood, 2021, 137, 2021-2032.	0.6	20
190	The Evolving Genomic Landscape of Esophageal Squamous Cell Carcinoma Under Chemoradiotherapy. Cancer Research, 2021, 81, 4926-4938.	0.4	20
191	Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation. JCI Insight, 2022, 7, .	2.3	20
192	Deep Sequencing in Cancer Research. Japanese Journal of Clinical Oncology, 2013, 43, 110-115.	0.6	19
193	Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia. Blood Advances, 2018, 2, 2879-2889.	2.5	19
194	Associations of complementation group, ALDH2 genotype, and clonal abnormalities with hematological outcome in Japanese patients with Fanconi anemia. Annals of Hematology, 2019, 98, 271-280.	0.8	19
195	Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study. Annals of Hematology, 2019, 98, 83-91.	0.8	19
196	The HTLV-1 viral oncoproteins Tax and HBZ reprogram the cellular mRNA splicing landscape. PLoS Pathogens, 2021, 17, e1009919.	2.1	19
197	Impact of <scp>SNP</scp> array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases. American Journal of Hematology, 2016, 91, 185-192.	2.0	18
198	<i>ASXL2</i> mutations are frequently found in pediatric AML patients with t(8;21)/ <i>RUNX1â€RUNX1T1</i> and associated with a better prognosis. Genes Chromosomes and Cancer, 2017, 56, 382-393.	1.5	18

#	Article	IF	Citations
199	Common Variable Immunodeficiency Caused by FANC Mutations. Journal of Clinical Immunology, 2017, 37, 434-444.	2.0	18
200	Acquired expression of CblQ367P in mice induces dysplastic myelopoiesis mimicking chronic myelomonocytic leukemia. Blood, 2017, 129, 2148-2160.	0.6	18
201	Metachronous anaplastic sarcoma of the kidney and thyroid follicular carcinoma as manifestations of DICER1 abnormalities. Human Pathology, 2017, 61, 205-209.	1.1	18
202	Diagnostic challenge of Diamond–Blackfan anemia in mothers and children by whole-exome sequencing. International Journal of Hematology, 2017, 105, 515-520.	0.7	18
203	Genetic heterogeneity of uncharacterized childhood autoimmune diseases with lymphoproliferation. Pediatric Blood and Cancer, 2018, 65, e26831.	0.8	18
204	Genome-Wide Analysis of Ocular Adnexal Lymphoproliferative Disorders Using High-Resolution Single Nucleotide Polymorphism Array., 2015, 56, 4156.		17
205	Structural Determinants of the Gain-of-Function Phenotype of Human Leukemia-associated Mutant CBL Oncogene. Journal of Biological Chemistry, 2017, 292, 3666-3682.	1.6	17
206	KLF1 mutation E325K induces cell cycle arrest in erythroid cells differentiated from congenital dyserythropoietic anemia patient-specific induced pluripotent stem cells. Experimental Hematology, 2019, 73, 25-37.e8.	0.2	17
207	Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms. Leukemia, 2021, 35, 2371-2381.	3.3	17
208	Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair–deficient colorectal cancer tissue. JCI Insight, 2021, 6, .	2.3	17
209	PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma. Clinical Cancer Research, 2019, 25, 3589-3601.	3.2	16
210	Frequent Loss of the Cyclin-dependent Kinase-4 Inhibitor Gene in Human Gliomas. Japanese Journal of Cancer Research, 1995, 86, 342-346.	1.7	15
211	Generation of HLA-DRB1*1501-restricted p190 minor bcr-abl (e1a2)-specific CD4+ T lymphocytes. British Journal of Haematology, 2000, 109, 435-437.	1.2	15
212	Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia. International Journal of Hematology, 2018, 107, 201-210.	0.7	15
213	RUNX1 mutations in pediatric acute myeloid leukemia are associated with distinct genetic features and an inferior prognosis. Blood, 2018, 131, 2266-2270.	0.6	15
214	ASXL2 regulates hematopoiesis in mice and its deficiency promotes myeloid expansion. Haematologica, 2018, 103, 1980-1990.	1.7	15
215	Integrated genetic and epigenetic analysis revealed heterogeneity of acute lymphoblastic leukemia in Down syndrome. Cancer Science, 2019, 110, 3358-3367.	1.7	15
216	<i>VAV1</i> mutations contribute to development of T-cell neoplasms in mice. Blood, 2020, 136, 3018-3032.	0.6	15

#	Article	lF	CITATIONS
217	A frequent nonsense mutation in exon 1 across certain HLA-A and -B alleles in leukocytes of patients with acquired aplastic anemia. Haematologica, 2021, 106, 1581-1590.	1.7	15
218	A histone modifier, ASXL1, interacts with NONO and is involved in paraspeckle formation in hematopoietic cells. Cell Reports, 2021, 36, 109576.	2.9	15
219	Molecular characterization of the genomic breakpoints in a case of t(3;21)(q26;q22)., 1999, 26, 92-96.		14
220	Cbl-family ubiquitin ligases and their recruitment of CIN85 are largely dispensable for epidermal growth factor receptor endocytosis. International Journal of Biochemistry and Cell Biology, 2014, 57, 123-134.	1.2	14
221	Induction of HLAâ€B*40:02â€restricted T cells possessing cytotoxic and suppressive functions against haematopoietic progenitor cells from a patient with severe aplastic anaemia. British Journal of Haematology, 2016, 172, 131-134.	1.2	14
222	Immune-Mediated Hematopoietic Failure after Allogeneic Hematopoietic Stem Cell Transplantation: A Common Cause of Late Graft Failure in Patients with Complete Donor Chimerism. Biology of Blood and Marrow Transplantation, 2018, 24, 43-49.	2.0	14
223	Clonally related diffuse large B-cell lymphoma and interdigitating dendritic cell sarcoma sharing MYC translocation. Haematologica, 2018, 103, e553-e556.	1.7	14
224	DNA methylation-based classification reveals difference between pediatric T-cell acute lymphoblastic leukemia and normal thymocytes. Leukemia, 2020, 34, 1163-1168.	3.3	14
225	Landscape Of Genetic Lesions In 944 Patients With Myelodysplastic Syndromes. Blood, 2013, 122, 521-521.	0.6	14
226	Somatic mosaicism in chronic myeloid leukemia in remission. Blood, 2016, 128, 2863-2866.	0.6	13
227	Decreased RORC expression and downstream signaling in HTLVâ€1â€associated adult Tâ€cell lymphoma/leukemia uncovers an antiproliferative IL17 link: A potential target for immunotherapy?. International Journal of Cancer, 2019, 144, 1664-1675.	2.3	13
228	Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes. American Journal of Hematology, 2020, 95, 133-143.	2.0	13
229	RNAmut: robust identification of somatic mutations in acute myeloid leukemia using RNA-sequencing. Haematologica, 2020, 105, e290-e293.	1.7	13
230	Indolent feature ofÂHelicobacter pylori-uninfected intramucosal signet ring cell carcinomas withÂCDH1Âmutations. Gastric Cancer, 2021, 24, 1102-1114.	2.7	13
231	Biological Analysis of SRSF2 Mutations in Leukemogenesis. Blood, 2012, 120, 1282-1282.	0.6	13
232	Aged healthy mice acquire clonal hematopoiesis mutations. Blood, 2022, 139, 629-634.	0.6	13
233	The landscape of genetic aberrations in myxofibrosarcoma. International Journal of Cancer, 2022, 151, 565-577.	2.3	13
234	Frameshift Mutations of thehMSH6Gene in Human Leukemia Cell Lines. Japanese Journal of Cancer Research, 1998, 89, 33-39.	1.7	12

#	Article	IF	CITATIONS
235	Whole-exome sequence analysis of ataxia telangiectasia-like phenotype. Journal of the Neurological Sciences, 2014, 340, 86-90.	0.3	12
236	Single cell genotyping of exome sequencing-identified mutations to characterize the clonal composition and evolution of inv(16) AML in a CBL mutated clonal hematopoiesis. Leukemia Research, $2016, 47, 41-46$ .	0.4	12
237	Genomic analysis of clonal origin of Langerhans cell histiocytosis following acute lymphoblastic leukaemia. British Journal of Haematology, 2016, 175, 169-172.	1.2	12
238	Adults with germline CBL mutation complicated with juvenile myelomonocytic leukemia at infancy. Journal of Human Genetics, 2016, 61, 523-526.	1.1	12
239	Glucagonoma With Necrolytic Migratory Erythema: Metabolic Profile and Detection of Biallelic Inactivation of DAXX Gene. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2417-2423.	1.8	12
240	Paraneoplastic hypereosinophilic syndrome associated with <i>IL3â€IgH</i> positive acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2019, 66, e27449.	0.8	12
241	Genetic basis of myelodysplastic syndromes. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2020, 96, 107-121.	1.6	12
242	Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas. Leukemia and Lymphoma, 2021, 62, 95-103.	0.6	12
243	Clonal hematopoiesis in adult pure red cell aplasia. Scientific Reports, 2021, 11, 2253.	1.6	12
244	Hemophagocytic syndrome associated with non-hodgkin's lymphoma of B-cell type. American Journal of Hematology, 1994, 47, 335-336.	2.0	11
245	Increased Serum Soluble Fas Ligand Associated with Recurrent B-Cell Non-Hodgkin's Lymphoma after Autologous Peripheral Blood Stem Cell Transplantation. Leukemia and Lymphoma, 1999, 34, 625-628.	0.6	11
246	Gain-of-function <i>c-CBL</i> mutations associated with uniparental disomy of 11q in myeloid neoplasms. Cell Cycle, 2010, 9, 1051-1056.	1.3	11
247	A case of malignant rhabdoid tumor mimicking yolk sac tumor. Pediatric Blood and Cancer, 2019, 66, e27784.	0.8	11
248	Clinical utility of target captureâ€based panel sequencing in hematological malignancies: A multicenter feasibility study. Cancer Science, 2020, 111, 3367-3378.	1.7	11
249	Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status. Blood Advances, 2020, 4, 845-854.	2.5	11
250	Association of high-risk neuroblastoma classification based on expression profiles with differentiation and metabolism. PLoS ONE, 2021, 16, e0245526.	1.1	11
251	CTX-712, a Novel Clk Inhibitor Targeting Myeloid Neoplasms with SRSF2 Mutation. Blood, 2019, 134, 404-404.	0.6	11
252	Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach. EBioMedicine, 2022, 78, 103963.	2.7	11

#	Article	IF	CITATIONS
253	Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies. Cancer Science, 2022, 113, 2763-2777.	1.7	11
254	The phenotype and clinical course of Japanese Fanconi Anaemia infants is influenced by patient, but not maternal <i>ALDH2</i> genotype. British Journal of Haematology, 2016, 175, 457-461.	1.2	10
255	Escape hematopoiesis by HLA-B5401-lacking hematopoietic stem progenitor cells in men with acquired aplastic anemia. Haematologica, 2019, 104, e447-e450.	1.7	10
256	A founder variant in the South Asian population leads to a high prevalence of <i>FANCL </i> Fanconi anemia cases in India. Human Mutation, 2020, 41, 122-128.	1.1	10
257	Reduced-intensity conditioning is effective for hematopoietic stem cell transplantation in young pediatric patients with Diamond–Blackfan anemia. Bone Marrow Transplantation, 2021, 56, 1013-1020.	1.3	10
258	Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia. Haematologica, 2021, , .	1.7	10
259	HLA class I allele–lacking leukocytes predict rare clonal evolution to MDS/AML in patients with acquired aplastic anemia. Blood, 2021, 137, 3576-3580.	0.6	10
260	Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1. Blood Cancer Discovery, 2021, 2, 450-467.	2.6	10
261	Truncation and microdeletion of <i>EVC</i> / <i>EVC2</i> with missense mutation of <i>EFCAB7</i> in Ellisâ€van Creveld syndrome. Congenital Anomalies (discontinued), 2016, 56, 209-216.	0.3	9
262	Copy number analysis identifies tumor suppressive lncRNAs in human osteosarcoma. International Journal of Oncology, 2017, 50, 863-872.	1.4	9
263	Constitutional abnormalities of <i>IDH1</i> combined with secondary mutations predispose a patient with Maffucci syndrome to acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2017, 64, e26647.	0.8	9
264	Comprehensive genetic analysis of pediatric germ cell tumors identifies potential drug targets. Communications Biology, 2020, 3, 544.	2.0	9
265	Classification of clear cell renal cell carcinoma based on PKM alternative splicing. Heliyon, 2020, 6, e03440.	1.4	9
266	Acquisition of monosomy 7 and a <i>RUNX1</i> mutation in Pearson syndrome. Pediatric Blood and Cancer, 2021, 68, e28799.	0.8	9
267	Chromatin-Spliceosome Mutations in Acute Myeloid Leukemia. Cancers, 2021, 13, 1232.	1.7	9
268	Genetic biomarkers for PD-1/PD-L1 blockade therapy. Oncoscience, 2016, 3, 311-312.	0.9	9
269	Gain-of-Function Mutations and Copy Number Increases of Notch2 in Diffuse Large B-Cell Lymphoma Blood, 2007, 110, 695-695.	0.6	9
270	Whole-exome analysis to detect congenital hemolytic anemia mimicking congenital dyserythropoietic anemia. International Journal of Hematology, 2018, 108, 306-311.	0.7	8

#	Article	IF	CITATIONS
271	Modification of cellular and humoral immunity by somatically reverted T cells in X-linked lymphoproliferative syndrome type 1. Journal of Allergy and Clinical Immunology, 2019, 143, 421-424.e11.	1.5	8
272	Noonan syndromeâ€associated biallelic <i>LZTR1</i> mutations cause cardiac hypertrophy and vascular malformations in zebrafish. Molecular Genetics & Enomic Medicine, 2020, 8, e1107.	0.6	8
273	Discovery of Functional Alternatively Spliced PKM Transcripts in Human Cancers. Cancers, 2021, 13, 348.	1.7	8
274	Stratification of patients with clear cell renal cell carcinoma to facilitate drug repositioning. IScience, 2021, 24, 102722.	1.9	8
275	Frequent Pathway Mutations of Splicing Machinery in Myelodysplasia. Blood, 2011, 118, 458-458.	0.6	8
276	Growth inhibition of leukaemic cells carrying the t(3;21) by the AML1/EVI-1 -specific antisense oligonucleotide. British Journal of Haematology, 1995, 90, 711-714.	1.2	7
277	Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis. International Journal of Hematology, 2018, 108, 447-451.	0.7	7
278	Fusion partner–specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML. Blood Advances, 2020, 4, 4623-4631.	2.5	7
279	Predisposed genomic instability in pre-treatment bone marrow evolves to therapy-related myeloid neoplasms in malignant lymphoma. Haematologica, 2020, 105, e337-e339.	1.7	7
280	Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas. Cancer Research, 2021, 81, 4861-4873.	0.4	7
281	Clinical Impacts of Germline <i>DDX41</i> Mutations on Myeloid Neoplasms. Blood, 2020, 136, 38-40.	0.6	7
282	SRSF2 is Mutated in 47.2% (77/163) of Chronic Myelomonocytic Leukemia (CMML) and Prognostically Favorable in Cases with Concomitant RUNX1 mutations. Blood, 2011, 118, 274-274.	0.6	7
283	Frequent but Reversible and Manageable Cardiac Complications after Successful Haploidentical HLA-Mismatched Hematopoietic Stem Cell Transplantation (HSCT) without Ex Vivo Graft Manipulation Blood, 2004, 104, 1841-1841.	0.6	7
284	Clonal Hematopoiesis: Cell of Origin, Lineage Repartition and Dynamic Evolution during Chemotherapy. Blood, 2017, 130, 632-632.	0.6	7
285	Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of <i>SF3B1</i> -mutant HSPCs. Blood Advances, 2022, 6, 2992-3005.	2.5	7
286	Genome-wide DNA methylation analysis in pediatric acute myeloid leukemia. Blood Advances, 2022, 6, 3207-3219.	2.5	7
287	Expansion of Gastric Intestinal Metaplasia with Copy Number Aberrations Contributes to Field Cancerization. Cancer Research, 2022, 82, 1712-1723.	0.4	7
288	Amplified <i>EPOR</i> / <i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia. Blood Cancer Discovery, 2022, 3, 410-427.	2.6	7

#	Article	IF	Citations
289	MDS-related mutations in aplastic anemia. Blood, 2014, 124, 2619-2620.	0.6	6
290	Molecular studies reveal MLL-MLLT10/AF10 and ARID5B-MLL gene fusions displaced in a case of infantile acute lymphoblastic leukemia with complex karyotype. Oncology Letters, 2017, 14, 2295-2299.	0.8	6
291	Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern. Blood Advances, 2019, 3, 3111-3122.	2.5	6
292	Prominence of nestin-expressing Schwann cells in bone marrow of patients with myelodysplastic syndromes with severe fibrosis. International Journal of Hematology, 2019, 109, 309-318.	0.7	6
293	Hematopoietic stem progenitor cells lacking HLA differ from those lacking GPI-anchored proteins in the hierarchical stage and sensitivity to immune attack in patients with acquired aplastic anemia. Leukemia, 2021, 35, 3257-3267.	3.3	6
294	A Possible Association Between a Nucleotideâ€Binding Domain LRRâ€Containing Protein Family PYDâ€Containing Protein 1 Mutation and an Autoinflammatory Disease Involving Liver Cirrhosis. Hepatology, 2021, 74, 2296-2299.	3.6	6
295	Comprehensive Analysis of Aberrant RNA Splicing in Myelodysplastic Syndromes. Blood, 2014, 124, 826-826.	0.6	6
296	<i>Toll-like receptor</i> genetic variations in bone marrow transplantation. Oncotarget, 2017, 8, 45670-45686.	0.8	6
297	A high prevalence of myeloid malignancies in progeria with Werner syndrome is associated with p53 insufficiency. Experimental Hematology, 2022, 109, 11-17.	0.2	6
298	Genetic Analysis of Pheochromocytoma and Paraganglioma Complicating Cyanotic Congenital Heart Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2545-2555.	1.8	6
299	Blastic transformation of juvenile myelomonocytic leukemia caused by the copy number gain of oncogenic <i>KRAS</i> . Pediatric Blood and Cancer, 2017, 64, e26496.	0.8	5
300	A Cryptic NUP214-ABL1 Fusion in B-cell Precursor Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2018, 40, e397-e399.	0.3	5
301	Genome analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki. Haematologica, 2020, 105, 358-365.	1.7	5
302	TET2 haploinsufficiency alters reprogramming into induced pluripotent stem cells. Stem Cell Research, 2020, 44, 101755.	0.3	5
303	Absence of a common founder mutation in patients with cooccurring myelodysplastic syndrome and plasma cell disorder. Blood, 2021, 137, 1260-1263.	0.6	5
304	Germline RUNX1 translocation in familial platelet disorder with propensity to myeloid malignancies. Annals of Hematology, 2022, 101, 237-239.	0.8	5
305	SNP Karyotyping in Myelodysplastic Syndromes (MDS) Reveals the Presence of Cryptic Karyotypic Abnormalities, Including Uniparental Disomy, and Has Important Prognostic Implications Blood, 2006, 108, 853-853.	0.6	5
306	Progression to polythythemia vera from familial thrombocytosis with germline JAK2 R867Q mutation. Annals of Hematology, 2018, 97, 737-739.	0.8	4

#	Article	IF	Citations
307	Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia. Leukemia Research, 2018, 65, 34-41.	0.4	4
308	Duplication of ALK F1245 missense mutation due to acquired uniparental disomy associated with aggressive progression in a patient with relapsed neuroblastoma. Oncology Letters, 2019, 17, 3323-3329.	0.8	4
309	Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome. Internal Medicine, 2020, 59, 1081-1086.	0.3	4
310	Nextâ€generation sequencing in two cases of <i>de novo</i> acute basophilic leukaemia. Journal of Cellular and Molecular Medicine, 2021, 25, 7095-7099.	1.6	4
311	Genetic features of Bâ€cell lymphoblastic lymphoma with <scp><i>TCF3â€PBX1</i></scp> . Cancer Reports, 2022, 5, e1559.	0.6	4
312	Somatic Mutations in Schinzel-Giedion Syndrome Gene SETBP1 Determine Progression in Myeloid Malignancies. Blood, 2012, 120, 2-2.	0.6	4
313	In Analogy to AML, MDS Can be Sub-Classified By Ancestral Mutations. Blood, 2014, 124, 823-823.	0.6	4
314	<i>NUDT15</i> variants confer high incidence of second malignancies in children with acute lymphoblastic leukemia. Blood Advances, 2021, 5, 5420-5428.	2.5	4
315	Tâ€cell lymphoma, Bâ€cell lymphoma, and myelodysplastic syndrome harboring common mutations: Trilineage tumorigenesis from a common founder clone. EJHaem, 2022, 3, 211-214.	0.4	4
316	Oncogenic <i>FGFR1</i> mutation and amplification in common cellular origin in a composite tumor with neuroblastoma and pheochromocytoma. Cancer Science, 2022, 113, 1535-1541.	1.7	4
317	Sudden Intracranial Hemorrhage in a Patient With Atypical Chronic Myeloid Leukemia in Chronic Phase. Journal of Pediatric Hematology/Oncology, 2018, 40, e553-e556.	0.3	3
318	Identification of a Novel Titin Variant Underlying Myocardial Involvement in Neurofibromatosis Type 1. Canadian Journal of Cardiology, 2018, 34, 1369.e5-1369.e7.	0.8	3
319	Acute myeloid leukemia with a cryptic NUP98/PRRX2 rearrangement developing after low-dose methotrexate therapy for rheumatoid arthritis. Annals of Hematology, 2019, 98, 2841-2843.	0.8	3
320	XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis. Blood Cancer Journal, 2021, 11, 27.	2.8	3
321	Clonal evidence for the development of neuroblastoma with extensive copyâ€neutral loss of heterozygosity arising in a mature teratoma. Cancer Science, 2021, 112, 2921-2927.	1.7	3
322	Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population. Cancer Science, 2021, 112, 3338-3348.	1.7	3
323	High Density SNP Arrays Reveal That Distinct Clonal Lesions Including Uniparental Disomy Can Be Detected in a Proportion of Patients with Aplastic Anemia with Normal Metaphase Cytogenetics Blood, 2006, 108, 125-125.	0.6	3
324	Reduced Tet2 Function Contributes to Development of Peripheral T-Cell Lymphoma with Follicular Helper T-Cell-Like Features in Mice. Blood, 2012, 120, 1299-1299.	0.6	3

#	Article	IF	CITATIONS
325	Alteration of the immune environment in bone marrow from children with recurrent B cell precursor acute lymphoblastic leukemia. Cancer Science, 2021, , .	1.7	3
326	Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia. Blood, 2020, 136, 17-18.	0.6	3
327	Prognostic Relevance of Genetic Abnormalities in Blastic Transformation of Chronic Myeloid Leukemia. Blood, 2020, 136, 3-4.	0.6	3
328	Complete Bone Marrow Necrosis with Charcot-Leyden Crystals Caused by Myeloid Neoplasm with Mutated <i>NPM1</i> and <i>TET2</i> . Internal Medicine, 2022, 61, 3265-3269.	0.3	3
329	Description of longitudinal tumor evolution in a case of multiply relapsed clear cell sarcoma of the kidney. Cancer Reports, 2022, 5, e1458.	0.6	3
330	Novel TENM3–ALK fusion is an alternate mechanism for ALK activation in neuroblastoma. Oncogene, 2022, 41, 2789-2797.	2.6	3
331	Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR15. Leukemia, 2022, 36, 1666-1675.	3.3	3
332	Atypical dyskeratosis congenita diagnosed using wholeâ€exome sequencing. Pediatrics International, 2017, 59, 933-935.	0.2	2
333	Hidden <i>FLT3</i> -D835Y clone in <i>FLT3</i> -ITD-positive acute myeloid leukemia that evolved into very late relapse with T-lymphoblastic leukemia. Leukemia and Lymphoma, 2018, 59, 1490-1493.	0.6	2
334	Two siblings with familial neuroblastoma with distinct clinical phenotypes harboring an <i>ALK</i> germline mutation. Genes Chromosomes and Cancer, 2018, 57, 665-669.	1.5	2
335	A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation. Case Reports in Oncology, 2020, 13, 449-455.	0.3	2
336	Deciphering the Clonal Origin of Relapsed Acute Lymphoblastic Leukemia in Children. Blood Cancer Discovery, 2020, 1, 21-22.	2.6	2
337	Distinct, Ethnic, Clinical, and Genetic Characteristics of Myelodysplastic Syndromes with Der(1;7). Blood, 2019, 134, 5392-5392.	0.6	2
338	Mutational Spectrum Analysis of Interesting Correlation and Interrelationship Between RNA Splicing Pathway and Commonly Targeted Genes in Myelodysplastic Syndrome. Blood, 2011, 118, 273-273.	0.6	2
339	Mutation Screening Associated with Chromosome 7 Abnormalities Using Next Generation Whole Exome Sequencing. Blood, 2012, 120, 173-173.	0.6	2
340	Clinical "MUTATOME―Of Myelodysplastic Syndrome; Comparison To Primary Acute Myelogenous Leukemia. Blood, 2013, 122, 518-518.	0.6	2
341	Somatic G17V Rhoa Mutation Specifies Angioimmunoblastic T-Cell Lymphoma. Blood, 2013, 122, 815-815.	0.6	2
342	ZRSR2 Mutations Cause Dysregulated RNA Splicing in MDS. Blood, 2014, 124, 4609-4609.	0.6	2

#	Article	IF	Citations
343	Genetic Background of Idiopathic Bone Marrow Failure Syndromes in Children. Blood, 2015, 126, 3610-3610.	0.6	2
344	Rearrangement and Deletion of the PAX5 Gene in Pediatric Acute B-Cell Lineage Lymphoblastic Leukemia Blood, 2007, 110, 981-981.	0.6	2
345	Resistance of KIR Ligand–Missing Leukocytes to NK Cells In Vivo in Patients with Acquired Aplastic Anemia. ImmunoHorizons, 2020, 4, 430-441.	0.8	2
346	EPOR/JAK/STAT Signaling Pathway As Therapeutic Target of Acute Erythroid Leukemia. Blood, 2021, 138, 610-610.	0.6	2
347	Molecular Cytogenetic Analyses of HIG, a Novel Human Cell Line Carrying $t(1;3)$ (p36.3;q25.3) Established from a Patient with Chronic Myelogenous Leukemia in Blastic Crisis. International Journal of Hematology, 2003, 78, 432-438.	0.7	1
348	ALDH2 polymorphism in patients with Diamond-Blackfan anemia in Japan. International Journal of Hematology, 2016, 103, 112-114.	0.7	1
349	Partial monosomy of 10p and duplication of another chromosome in two patients. Pediatrics International, 2017, 59, 99-102.	0.2	1
350	Remission clone in acute myeloid leukemia shows growth advantage after chemotherapy but is distinct from leukemic clone. Experimental Hematology, 2019, 75, 26-30.	0.2	1
351	Persistent clonal cytogenetic abnormality with del(20q) from an initial diagnosis of acute promyelocytic leukemia. International Journal of Hematology, 2020, 111, 311-316.	0.7	1
352	Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy. International Journal of Hematology, 2021, 113, 936-940.	0.7	1
353	Poor Myocardial Compaction in a Patient with Recessive <i>MYL2</i> Myopathy. International Heart Journal, 2021, 62, 445-447.	0.5	1
354	Targeted deep next generation sequencing identifies potential somatic and germline variants for predisposition to familial Burkitt lymphoma. European Journal of Haematology, 2021, 107, 166-169.	1.1	1
355	Dramatic response to encorafenib in a patient with <scp>E</scp> rdheimâ€" <scp>C</scp> hester disease harboring the <scp><i>BRAF</i><sup>V600E</sup></scp> mutation. American Journal of Hematology, 2021, 96, E295-E298.	2.0	1
356	A growing genetic tree in the soil of prostate. Cell Stem Cell, 2021, 28, 1185-1187.	5.2	1
357	Molecular characterization of the genomic breakpoints in a case of t(3;21)(q26;q22)., 1999, 26, 92.		1
358	Identification of Chromosomal Abnormalities in Healthy Bone Marrow Using 250K SNP Arrays Blood, 2006, 108, 2076-2076.	0.6	1
359	Whole Exome Sequencing to Predict Response to Hypomethylating Agents in MDS. Blood, 2012, 120, 1698-1698.	0.6	1
360	Genetic Basis of Myeloid Proliferation Related to Down Syndrome. Blood, 2012, 120, 535-535.	0.6	1

#	Article	IF	Citations
361	Hypermethylation of Bcl6 Is a Potential Cause of Development of Lymphoma with Tfh Features in Tet2 Knockdown Mice. Blood, 2013, 122, 2490-2490.	0.6	1
362	PRPF8 Defects Cause Missplicing In Myeloid Malignancies. Blood, 2013, 122, 2838-2838.	0.6	1
363	Spliceosomal Gene LUC7L2 Mutation Causes Missplicing and Alteration Of Gene Expression In Myeloid Neoplasms. Blood, 2013, 122, 470-470.	0.6	1
364	Identification of an asymptomatic Shwachman–Bodian–Diamond syndrome mutation in a patient with acute myeloid leukemia. International Journal of Hematology, 2021, , 1.	0.7	1
365	Maturing papillomatous nevoid melanoma in the scalp mimicking recurrent melanocytic nevus: A case report of previously undescribed subtype of nevoid melanoma. Pathology International, 2021, , .	0.6	1
366	Recurrent Mutations of Multiple Components of Cohesin Complex in Myeloid Neoplasms. Blood, 2012, 120, 782-782.	0.6	1
367	Identification of Two New DBA Genes, RPS27 and RPL27, by Whole-Exome Sequencing in Diamond-Blackfan Anemia Patients. Blood, 2012, 120, 984-984.	0.6	1
368	Various Germline Congenital Disorder Genes Are Somatically Mutated in Myeloid Malignancies. Blood, 2012, 120, 1405-1405.	0.6	1
369	Identification of Cell-Type-Specific Mutations in Angioimmunoblastic T-Cell Lymphoma. Blood, 2014, 124, 3025-3025.	0.6	1
370	Prognostic model of lower grade gliomas Journal of Clinical Oncology, 2015, 33, 2038-2038.	0.8	1
371	Recurrent VAV1 Abnormalities in Angioimmunoblastic T Cell Lymphoma. Blood, 2016, 128, 4104-4104.	0.6	1
372	Biological Characterization of the U2af1 S34F Mutation in the Pathogenesis of Myelodysplasia. Blood, 2018, 132, 3080-3080.	0.6	1
373	Distinct Pathogenesis of Clonal Hematopoiesis Revealed By Single Cell RNA Sequencing Integrated with Highly Sensitive Genotyping Method. Blood, 2020, 136, 34-34.	0.6	1
374	Preclinical Evaluation of a Novel MALT1 Inhibitor CTX-177 for Relapse/Refractory Lymphomas. Blood, 2020, 136, 3-4.	0.6	1
375	Functional Characterization of Compound DDX41 Germline and Somatic R525H Mutations in the Development of Myeloid Malignancies. Blood, 2020, 136, 21-22.	0.6	1
376	Dyserythropoietic anaemia with an intronic GATA1 splicing mutation in patients suspected to have Diamondâ€Blackfan anaemia. EJHaem, 2022, 3, 163-167.	0.4	1
377	Childhood acute myeloid leukemia with 5q deletion and <i>HNRNPH1-MLLT10</i> fusion: the first case report. Blood Advances, 2022, 6, 3162-3166.	2.5	1
378	Emergence of t(3;21)(q26.2;q22) during eltrombopag treatment in a patient with relapsed aplastic anemia who received chemotherapy for angioimmunoblastic T-cell lymphoma. Leukemia Research Reports, 2022, 17, 100305.	0.2	1

#	Article	IF	Citations
379	GE-34 * THE MUTATIONAL LANDSCAPE AND TEMPORAL AND SPATIAL CLONAL EVOLUTION TO PROGRESSION IN 351 LOW-GRADE GLIOMAS. Neuro-Oncology, 2014, 16, v103-v104.	0.6	0
380	Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohort. British Journal of Haematology, 2020, 191, 755-763.	1.2	0
381	Clonal Cytopenia of Undetermined Significance in a Patient with Congenital Wilms' Tumor 1 and Acquired DNMT3A Gene Mutations. Internal Medicine, 2021, 60, 3785-3788.	0.3	0
382	Essential thrombocythaemia with aggressive megakaryocytosis after myelofibrotic transformation. Hematology, 2021, 26, 594-600.	0.7	0
383	Successful treatment of hepatosplenic T-cell lymphoma with fludarabine, high-dose cytarabine and subsequent unrelated umbilical cord blood transplantation. International Journal of Hematology, 2021, , 1.	0.7	0
384	Ki23819 (KRN383•HCl) Inhibits Kinase Activity of Wild Type and Mutant FLT3 Receptor Tyrosine Kinase In Vitro Blood, 2004, 104, 1168-1168.	0.6	0
385	Cas-L/Hef1 Is Required for Marginal Zone B Cell Maintenance and Lymphocyte Trafficking Blood, 2005, 106, 3920-3920.	0.6	0
386	Genome-Wide Analysis of Copy Number Alterations/LOH/Allelic Imbalances in Non-Hodgkin Lymphoma Using Ultrahigh-Density SNP-Genotyping Microarrays with the Robust CNAG Algorithms Blood, 2005, 106, 420-420.	0.6	0
387	Genome-Wide Analysis of Copy Number Analysis of Myelodysplastic Syndromes Using High-Density SNP-Genotyping Microarrays Blood, 2005, 106, 3420-3420.	0.6	0
388	Cas-L Suppresses Progression of Leukemia Induced by p210Bcr/Abl Blood, 2006, 108, 4816-4816.	0.6	0
389	SNP Array Analysis in Refractory Anemia with Ringed Sideroblast Allows for Detection of a High Frequency of Previously Cryptic Chromosomal Defects with Possible Clinical Significance Blood, 2006, 108, 2352-2352.	0.6	0
390	AML1/Runx1 Negatively Regulates the Number of Quiescent Hematopoietic Stem Cells in Adult Hematopoiesis Blood, 2006, 108, 4204-4204.	0.6	0
391	Whole Genome 250K SNP Array Allows for Detection of Previously Unidentified Lesions in Chromosome 5 in Patients with MDS Blood, 2006, 108, 2350-2350.	0.6	0
392	Genetic Profiling of Myeloproliferative Disorders by Single Nucleotide Polymorphism Oligonucleotide Microarray Blood, 2006, 108, 2688-2688.	0.6	0
393	Evi-1 Is Essential for Expansion and Maintenance of Hematopoietic Stem Cells Blood, 2006, 108, 783-783.	0.6	0
394	Highly Efficient Ex Vivo Expansion of Human Hematopoietic Stem Cells Using Delta1-Fc Chimeric Protein Blood, 2006, 108, 1332-1332.	0.6	0
395	Hidden Abnormalities and Novel Classification of $t(15;17)$ APL Based on Genomic Alterations Blood, 2007, 110, 4133-4133.	0.6	0
396	High Frequency of Loss of Heterozygosity Due to Uniparental Disomy or Allele Deletion of Ocular Adnexal MALT-Type Lymphoma Blood, 2007, 110, 2624-2624.	0.6	0

#	Article	IF	Citations
397	High-Resolution Analyses of Genetic and Epigenetic Aberrations in Infant Leukemia with MLL Rearrangement Blood, 2007, 110, 4238-4238.	0.6	O
398	Genetic Profiling of Adult Acute Lymphoblastic Leukemia Cells by Single Nucleotide Polymorphism Oligonucleotide Microarray Blood, 2007, 110, 2807-2807.	0.6	0
399	Implication of AML1/RUNX1 Function in the Homeostasis and Leukemic Transformation of Hematopoietic Stem Cells Blood, 2007, 110, 4117-4117.	0.6	O
400	Mutations of the Spliceosome Complex Genes Occur In Adult Patients but Are Very Rare In Children with Myeloid Neoplasia. Blood, 2011, 118, 2797-2797.	0.6	0
401	Functional Analysis of SRSF2 Mutations in Myelodysplastic Syndromes and Related Disorders. Blood, 2011, 118, 1706-1706.	0.6	0
402	TET2 Mutations Revealed by Whole Genome Sequencing in Adult T-Cell Leukemia Blood, 2012, 120, 2697-2697.	0.6	0
403	Whole Exome Sequencing Reveals Spectrum of Gene Mutations in Pediatric AML. Blood, 2012, 120, 124-124.	0.6	0
404	Molecular Diversity Detected by Whole Exome Sequencing in Chronic Myelomonocytic Leukemia. Blood, 2012, 120, 310-310.	0.6	0
405	Mutational Spectrum of Myelodysplastic Syndrome Malignancies Revealed by Whole Exome Sequencing. Blood, 2012, 120, 307-307.	0.6	O
406	Karyotypic and Genetic Abnormalities Associated with Clonal Evolution in Paroxysmal Nocturnal Hemoglobinuria Blood, 2012, 120, 2371-2371.	0.6	0
407	Whole Exome Analysis Reveals Spectrum of Gene Mutations in Juvenile Myelomonocytic Leukemia. Blood, 2012, 120, 170-170.	0.6	O
408	Pathway Mutations in the Splicing Machinery in Myeloid Neoplasms. Blood, 2012, 120, SCI-14-SCI-14.	0.6	0
409	Novel Recurrent Mutations in the Ras-Like GTP-Binding Gene Rit1 in Myeloid Malignancies. Blood, 2012, 120, 558-558.	0.6	0
410	Evidence That GPI-AP-Specific CTLs Are Not Involved In The "escape―Of Piga mutant Hematopoietic Stem Cells In Aplastic Anemia. Blood, 2013, 122, 1240-1240.	0.6	0
411	Whole Exome Sequencing Detecting Kinesin Family Gene Defects In Myeloid Neoplasm. Blood, 2013, 122, 2762-2762.	0.6	0
412	Concurrent Loss Of Ezh2 and Tet2 Cooperates In The Pathogenesis Of Myelodysplastic Disorders,. Blood, 2013, 122, 480-480.	0.6	0
413	Impact Of HLA Allele and Haplotype On Acute Graft-Versus-Host Disease and Survival After Hematopoietic Stem Cell Transplantation From Unrelated Donor. Blood, 2013, 122, 708-708.	0.6	O
414	Whole Exome Sequencing Shows a Paucity Of Somatic Gene Mutations In Pediatric Idiopathic Bone Marrow Failure Syndrome. Blood, 2013, 122, 3708-3708.	0.6	0

#	Article	IF	Citations
415	Somatic Mutations and Loss-Of-Heterozygosity Impair The DNA Repair Functions Of CUX1 in Myelodysplastic Syndromes (MDS). Blood, 2013, 122, 1246-1246.	0.6	O
416	A Novel Diagnostic Method For AITL By Detecting RHOA G17V Hotspot Mutation Using Allele-Specific Real-Time PCR. Blood, 2013, 122, 3000-3000.	0.6	0
417	Whole Exome Sequencing ("mutatomeâ€) Of Deletion 5q. Blood, 2013, 122, 656-656.	0.6	0
418	Whole Exome Analysis Of Germline Alterations Associated With Myelodysplastic Syndrome. Blood, 2013, 122, 2800-2800.	0.6	0
419	Genetic Landscapes Of Childhood T-Cell Acute Lymphoblastic Leukemia. Blood, 2013, 122, 3786-3786.	0.6	0
420	Clinical Features of Patients with ASXL1 and ASXL2 Mutations in Pediatric Acute Myeloid Leukemia. Blood, 2014, 124, 1024-1024.	0.6	0
421	The Clinical and Genetic Features of Dyskeratosis Congenita, Cryptic Dyskeratosis Congenita, and Hoyeraal-Hreidarsson Syndrome in Japan. Blood, 2014, 124, 1608-1608.	0.6	0
422	An Adverse Prognostic Effect of Homozygous TET2 Mutational Status on the Relapse Risk of Acute Myeloid Leukemia Patients of Normal Karyotype. Blood, 2014, 124, 1052-1052.	0.6	0
423	Chronic Myelomonocytic Leukemia (CMML) Can be Categorized By Ancestral Mutational Events. Blood, 2014, 124, 1893-1893.	0.6	0
424	Clinical and Molecular Significance of Peripheral Blood Cell-Free DNA in B-Cell Lymphomas for Detection of Genetic Mutations and Correlation with Disease Status. Blood, 2014, 124, 1658-1658.	0.6	0
425	Impact and Function of Somatic PHF6 Mutations in Myeloid Neoplasms. Blood, 2014, 124, 3581-3581.	0.6	0
426	Resistance of Hematopoietic Stem Cells Lacking the KIR Ligand to Autologous NK Cell Attacks in Patients with Acquired Aplastic Anemia. Blood, 2014, 124, 2939-2939.	0.6	0
427	Whole-Exome Sequencing Reveals a Paucity of Somatic Gene Mutations in Aplastic Anemia and Refractory Cytopenia of Childhood. Blood, 2014, 124, 4388-4388.	0.6	0
428	Molecular profiling of myelodysplastic syndromes. Tenri Medical Bulletin, 2015, 18, 1-16.	0.1	0
429	Long-term outcome of six months maintenance chemotherapy for ALL in children: TCCSG L92-13E study Journal of Clinical Oncology, 2015, 33, 10032-10032.	0.8	0
430	The landscape and clonal architecture in lower grade glioma Journal of Clinical Oncology, 2015, 33, 2008-2008.	0.8	0
431	Next-Generation Sequencing Reveal Proviral Genome and Transcriptome in Adult T-Cell Leukemia/Lymphoma. Blood, 2015, 126, 3882-3882.	0.6	0
432	COL4A1 is a Novel Causative Gene Responsible for Congenital Hemolytic Anemia, Representing Characteristic Clinical Course in Infants. Blood, 2015, 126, 934-934.	0.6	0

#	Article	IF	CITATIONS
433	Determinants of Phenotypic Commitment and Clonal ProgressionConclusions from the Study of Clonal Architecture in CMML. Blood, 2015, 126, 2848-2848.	0.6	0
434	Functional Characterization of a Novel GFI1B Mutation Causing Congenital Macrothrombocytopenia. Blood, 2015, 126, 75-75.	0.6	0
435	Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic Leukemia. Blood, 2015, 126, 1425-1425.	0.6	O
436	Myelodysplastic Syndrome Patients Show Mutation-Specific DNA Methylation Patterns. Blood, 2015, 126, 1646-1646.	0.6	0
437	Network-Based Analysis of Exome Sequencing Mutations Identifies Molecular Subtypes of Myelodysplastic Syndromes. Blood, 2015, 126, 611-611.	0.6	O
438	Gene Expression Profiles and Methylation Analysis in Down Syndrome Related Acute Lymphoblastic Leukemia. Blood, 2016, 128, 4084-4084.	0.6	0
439	ASXL2 Is Recurrently Mutated in t(8;21) AML and Regulates Hematopoietic Development. Blood, 2016, 128, 1051-1051.	0.6	O
440	Structural Variations Involving Programmed Death Ligands in B-Cell and T-Cell Lymphomas. Blood, 2016, 128, 4105-4105.	0.6	0
441	New targetes and biomarkers in hematological malignancies. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY22-3.	0.0	O
442	Analysis of Genomic Predispositions to Sporadic Myeloid Neoplasms Mediated By DDX41 in Japan. Blood, 2018, 132, 4371-4371.	0.6	0
443	Mutant ASXL1 Disrupts Paraspeckle Formation through Aberrant Interaction with Nono in Hematopoietic Cells. Blood, 2019, 134, 2514-2514.	0.6	O
444	Genomic analysis of two rare cases of pediatric Phâ€positive Tâ€ALL. Pediatric Blood and Cancer, 2022, 69, e29427.	0.8	0
445	ATRT-11. PREVALENCE OF GERMLINE VARIANTS IN SMARCB1 INCLUDING SOMATIC MOSAICISM IN AT/RT AND OTHER RHABDOID TUMORS. Neuro-Oncology, 2020, 22, iii277-iii278.	0.6	O
446	Functional Roles of <i>DDX41</i> Mutations in the Development of Myeloid Malignancies. Blood, 2021, 138, 150-150.	0.6	0
447	Distinct Pathogenesis of Clonal Hematopoiesis Revealed By Single Cell RNA Sequencing Integrated with Highly Sensitive Genotyping Method. Blood, 2021, 138, 1092-1092.	0.6	0
448	Clonal Evolution Pattern and Prognostic Significance of Clonal Architecture in KMT2A-Rearranged Acute Myeloid Leukemia. Blood, 2021, 138, 2358-2358.	0.6	0
449	NGS Evaluation of the Eqol-MDS Trial: Preliminary Analysis of Eltrombopag for Thrombocytopenia of Low-Risk MDS. Blood, 2021, 138, 1516-1516.	0.6	O
450	Analysis of Clonal Evolution of AML Using Simultaneous Single-Cell DNA/RNA Analysis. Blood, 2020, 136, 1-1.	0.6	0

#	ARTICLE	IF	CITATIONS
451	Clonal Hematopoiesis By HLA Class I Allele-Lacking Hematopoietic Stem Cells and Concomitant Aberrant Stem Cells Is Rarely Associated with Clonal Evolution to Secondary Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients with Acquired Aplastic Anemia. Blood, 2020, 136, 1-2.	0.6	0
452	<i>Post-Treatment Clone Size Predicts Survival Independently of IPSS-R and Response after Azacitidine Therapy for MDS.</i> <li>Blood, 2020, 136, 12-13.</li>	0.6	0
453	<i>ASXL1</i> Mutations Predict a Poor Response to Darbepoetin Alfa in Anemic Patients with Low-Risk MDS: A Multicenter, Phase II Study. Blood, 2020, 136, 28-29.	0.6	0
454	Whole-Genome Analysis of Adult T-Cell Leukemia/Lymphoma. Blood, 2020, 136, 29-30.	0.6	0
455	<i>KRAS</i> mutations Frequently Coexist with High-Risk <i>MLL</i> Fusions and Are Independent Adverse Prognostic Factors in <i>MLL</i> -Rearranged Acute Myeloid Leukemia. Blood, 2020, 136, 28-29.	0.6	0
456	Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms. EJHaem, $0,  ,  .$	0.4	0
457	Elderlyâ€onset systemic Epstein–Barr virusâ€positive Tâ€cell lymphoma of childhood. Pathology International, 2022, 72, 376-378.	0.6	0
458	Abstract 6198: Genetic analysis of synchronous or metachronous multiple pancreatic cancers. Cancer Research, 2022, 82, 6198-6198.	0.4	0
459	Abstract 6085: Clonal evolution of mammary epithelial cells into breast cancers. Cancer Research, 2022, 82, 6085-6085.	0.4	0
460	ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial. International Journal of Hematology, 0, , .	0.7	0